• EU green light for Chiesi’s Lamzede pharmatimes
    July 18, 2018
    European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
PharmaSources Customer Service